Q1 FY27 results analysis · July 31, 2026

Concord Biotech Ltd (CONCORDBIO) Q1 FY27 Results Analysis: Revenue Surges 26%, EBITDA Margin Expands 189 bps

+32.8%PAT year on year, Rs. 57.70 Cr
Cofacto ResearchPublished July 31, 20262 min readPositive read
Quick summary

Concord Biotech Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 257.49 Cr (+26.23% YoY) and PAT growth of +32.84% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 31, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 257.49 Cr (+26.23% YoY)
PAT (Q1)Rs. 57.70 Cr (+32.84% YoY)
EBITDA margin31.99% (+189 bps YoY)
EPS (Q1)Rs. 5.52 (+31.12% YoY)
Market capRs. 14,828.20 Cr
CMPRs. 1,420.80

Quarter Snapshot

Revenue grew 26.23% YoY, beating management's FY27 aspiration of >18% growth. EBITDA margin expanded 189 bps YoY to 31.99% with operating leverage visible. Cost pressures from other expenses (+41% YoY) and inventory build (Rs.26.85 Cr) temper the otherwise strong quarter. USFDA ANDA approvals provide incremental growth catalysts.

Key Investment Insights

Key Positives

  • Revenue grew 26.23% YoY to Rs.257.49 Cr, exceeding management's FY27 aspiration of >18% growth
  • EBITDA margin expanded 189 bps YoY to 31.99%
  • PAT attributable to owners grew 32.84% YoY to Rs.58.53 Cr
  • USFDA ANDA approvals for Tofacitinib Tablets and Mycophenolate Mofetil Oral Suspension in June 2026
  • Standalone revenue grew 27.71% YoY and PAT grew 43.74% YoY

Risk Factors

  • Other expenses grew 41.02% YoY, the fastest-growing cost line, potentially reflecting injectable facility and Stellon Biotech setup costs
  • Power and fuel costs rose 17.80% YoY and 16.67% QoQ, likely due to higher production volumes and/or tariff escalation
  • Revenue declined 21.03% QoQ, reflecting typical lumpiness in API procurement cycles
  • Inventory built by Rs.26.85 Cr, contradicting management's expectation of normalization within H1 FY27
  • Subsidiaries (Stellon Biotech, Celliimmune) remain a net drag of Rs.2.67 Cr on consolidated PAT

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.